Philip Morris (NYSE:PM) announced today that it agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion. New York–based Philip Morris agreed with the board of Vectura Group on the all-cash, recommended offer under which Vectura shareholders would be entitled to receive $2.07 per share (150 pence), representing a 46% premium to the […]
Thermo Fisher expands gene therapy portfolio
Thermo Fisher Scientific (NYSE:TMO) announced a new set of solutions to support adeno-associated viral (AAV) manufacturing. AAV, a non-pathogenic virus capable of infecting cells at various stages of growth, has become a preferred “viral vector” for delivering gene therapies, although the scalability of AAV remains a challenge. According to a news release, Thermo Fisher designed […]
Thermo Fisher Scientific expands corporate leadership team
Thermo Fisher Scientific (NYSE:TMO) announced today that it appointed Dr. Alan Sachs to chief medical officer and Karen E. Nelson to chief scientific officer. Sachs served as Waltham, Mass.-based Thermo Fisher’s CSO since 2016 and will be succeeded by Nelson as he assumes the newly established CMO position at the company. Both will join the […]
Fresenius Kabi launches Simplist fentanyl citrate injection
Fresenius Kabi announced today that it initiated the U.S. introduction of a fentanyl citrate injection in the Simplist pre-filled syringe. Lake Zurich, Ill.-based Fresenius Kabi’s proprietary Simplist ready-to-administer prefilled syringe offers the fentanyl citrate injection at 50 mcg per 1 mL in an effort to reduce waste and diversion while ensuring the safe delivery of […]
DarioHealth touts data for diabetes management platform
DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform. New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine. According to a news release, results —presented at the American Diabetes Association (ADA) 81st […]
Teva initiates U.S. recall of Topotecan metastatic ovarian cancer injection treatment
Teva Pharmaceuticals (NYSE:TEVA) initiated a voluntary recall of a lot of its Topotecan injection 4mg/4mL (1mg/mL) in the U.S. The voluntary recall came as a result of a complaint received from a pharmacy after a single glass particle was observed inside one vial. Following further examination of the complaint sample, two other particulates were found […]
PharmaJet begins enrollment for needle-free COVID-19 vaccine trial
PharmaJet announced today that it began enrollment for a Phase 1 clinical trial for its needle-free COVID-19 vaccine in Australia. Golden, Colo.-based PharmaJet’s needle-free injection systems will be studied with Covigen, a DNA-based vaccine developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with Melbourne, Australia-based Technovalia. According to a news release, PharmaJet’s system was chosen […]
United Therapeutics touts study results for inhaled Tyvaso treatment
United Therapeutics (NSDQ:UTHR) today announced positive results from an analysis of forced vital capacity (FVC) change with its Tyvaso treatment. Research Triangle Park, N.C.–based United Therapeutics developed Tyvaso (treprostinil) as an inhalation solution for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA approved the treatment in April 2020. The posthoc analysis of […]
Giiant Pharma extends seed round with $1.25M
Giiant Pharma announced today that it added $1.25 million to its seed financing round to ensure reaching clinical proof-of-concept for its Precision Delivery technology platform. Montreal-based Giiant’s $750,000 in funding from AQC Capital, plus $500,000 from CQDM, adds to the seed round closed last month to bring the company’s total funding to nearly $15 million. […]
Charles River Laboratories completes $292.5M Vigene acquisition
Charles River Laboratories (NYSE:CRL) announced that it completed a $292.5 million acquisition of Vigene Biosciences. Rockville, Md.-based Vigene, a gene therapy contract development and manufacturing organization (CDMO), develops viral vector-based gene delivery systems, with a primary area of expertise in CGMP viral vector manufacturing for gene therapies and gene-modified cell therapies. According to a news […]